JP2012528170A - 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法 - Google Patents

別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法 Download PDF

Info

Publication number
JP2012528170A
JP2012528170A JP2012513184A JP2012513184A JP2012528170A JP 2012528170 A JP2012528170 A JP 2012528170A JP 2012513184 A JP2012513184 A JP 2012513184A JP 2012513184 A JP2012513184 A JP 2012513184A JP 2012528170 A JP2012528170 A JP 2012528170A
Authority
JP
Japan
Prior art keywords
dapagliflozin
inhibitor
insulin
per day
sglt2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012513184A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012528170A5 (enExample
Inventor
ポール・ストランプ
ステファニー・モラン
ジェイムズ・リスト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Bristol Myers Squibb Co
Original Assignee
AstraZeneca UK Ltd
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42334303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2012528170(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca UK Ltd, Bristol Myers Squibb Co filed Critical AstraZeneca UK Ltd
Publication of JP2012528170A publication Critical patent/JP2012528170A/ja
Publication of JP2012528170A5 publication Critical patent/JP2012528170A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012513184A 2009-05-27 2010-05-26 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法 Withdrawn JP2012528170A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18144209P 2009-05-27 2009-05-27
US61/181,442 2009-05-27
PCT/US2010/036120 WO2010138535A1 (en) 2009-05-27 2010-05-26 Methods for treating type 2 diabetes in patients resistant to previous treatment with other anti-diabetic drugs employing an sglt2 inhibitor and compositions thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015241499A Division JP2016104753A (ja) 2009-05-27 2015-12-10 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法

Publications (2)

Publication Number Publication Date
JP2012528170A true JP2012528170A (ja) 2012-11-12
JP2012528170A5 JP2012528170A5 (enExample) 2013-06-27

Family

ID=42334303

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012513184A Withdrawn JP2012528170A (ja) 2009-05-27 2010-05-26 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法
JP2015241499A Pending JP2016104753A (ja) 2009-05-27 2015-12-10 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法
JP2017074526A Pending JP2017160212A (ja) 2009-05-27 2017-04-04 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015241499A Pending JP2016104753A (ja) 2009-05-27 2015-12-10 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法
JP2017074526A Pending JP2017160212A (ja) 2009-05-27 2017-04-04 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法

Country Status (5)

Country Link
US (1) US8685934B2 (enExample)
EP (1) EP2435033A1 (enExample)
JP (3) JP2012528170A (enExample)
CN (2) CN106075451A (enExample)
WO (1) WO2010138535A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523681A (ja) * 2010-03-30 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用
JP2019504090A (ja) * 2016-02-03 2019-02-14 ドクター レディズ ラボラトリーズ リミテッド ダサチニブの固体状態形態およびそれらの調製プロセス
JP2019503983A (ja) * 2016-05-20 2019-02-14 センター ラボラトリーズ， インク．Ｃｅｎｔｅｒ Ｌａｂｏｒａｔｏｒｉｅｓ， Ｉｎｃ． 高血糖症を処置する方法

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20090938A1 (es) * 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
AP2011005794A0 (en) 2009-02-13 2011-08-31 Boehringer Ingelheim Int Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a furtherantidiabetic agent and uses thereof.
PL2483286T3 (pl) 2009-09-30 2017-04-28 Boehringer Ingelheim International Gmbh Sposób wytwarzania postaci krystalicznej 1-chloro-4-(β-D-glukopiranoz-1-ylo)-2-[4-((S)-tetrahydrofuran-3-yloksy)-benzylo]-benzenu
BR112012007085B8 (pt) 2009-09-30 2021-05-25 Boehringer Ingelheim Int processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila
UY32919A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
LT2498758T (lt) 2009-11-13 2018-11-26 Astrazeneca Ab Dvisluoksnės tabletės formuluotės
RS57926B1 (sr) 2009-11-13 2019-01-31 Astrazeneca Ab Formulacije tablete sa trenutnim oslobađanjem
US20120283169A1 (en) * 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
WO2013095316A1 (en) * 2011-12-19 2013-06-27 Mahmut Bilgic Synergic combination comprising anti-diabetic agent
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9320727B2 (en) * 2012-08-30 2016-04-26 Taisho Pharmaceutical Co., Ltd Combinations of SGLT 2 inhibitors and antihypertensive drugs
WO2014159151A1 (en) 2013-03-14 2014-10-02 Msd International Gmbh Methods for preparing sglt2 inhibitors
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HRP20190101T1 (hr) 2013-04-05 2019-03-08 Boehringer Ingelheim International Gmbh Terapeutske uporabe empagliflozina
HUE058731T2 (hu) 2013-04-18 2022-09-28 Boehringer Ingelheim Int Gyógyászati készítmények, kezelési eljárások és ezek alkalmazásai
EP2991999B1 (en) 2013-04-29 2019-05-08 Mapi Pharma Limited Dapagliflozin lactose co-crystal
CN104496952B (zh) * 2014-11-28 2017-04-19 深圳翰宇药业股份有限公司 一种达格列净的合成方法
CA2981507A1 (en) * 2015-04-07 2016-10-13 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
MX2019005435A (es) 2016-11-10 2019-07-10 Boehringer Ingelheim Int Composicion farmaceutica, metodos para tratamiento y sus usos.
WO2018167589A1 (en) 2017-03-16 2018-09-20 Inventia Healthcare Private Limited Pharmaceutical composition comprising dapagliflozin
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
BR112020010831A2 (pt) 2017-11-30 2020-11-10 Idorsia Pharmaceuticals Ltd composição farmacêutica, aprocitentan, e, método
US10639292B2 (en) 2018-04-20 2020-05-05 Center Laboratories, Inc. Method of treating hyperglycemia
KR102695130B1 (ko) 2018-05-31 2024-08-16 후아 메디슨 (상하이) 엘티디. 글루코키나제 활성화제 및 ppar 수용체 활성화제를 함유하는 약제학적 병용물, 조성물, 및 병용 제제, 및 이의 제조 방법 및 용도
WO2019241568A1 (en) * 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood sugar with a gliflozin sodium-glucose cotransporter 2 inhibitor pharmaceutical composition
BR112022012436A2 (pt) * 2019-12-24 2022-09-06 Hanmi Pharm Ind Co Ltd Formulação compósita e método para preparar a formulação compósita
IL297208A (en) * 2020-04-10 2022-12-01 Chinook Therapeutics Inc Treatment methods for diabetic kidney disease
JP2023523596A (ja) 2020-04-22 2023-06-06 バイエル アクチェンゲゼルシャフト 心血管疾患および／または腎疾患を治療および／または予防するためのフィネレノンとｓｇｌｔ２阻害剤の組み合わせ
KR102838283B1 (ko) * 2020-07-10 2025-07-25 한미약품 주식회사 시타글립틴 및 다파글리플로진을 포함하는 복합제제 및 그 제조방법
TW202220672A (zh) 2020-07-27 2022-06-01 瑞典商阿斯特捷利康公司 用達格列淨治療慢性腎臟病之方法
WO2022091029A1 (en) * 2020-10-30 2022-05-05 Resverlogix Corp. Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
CN114671839B (zh) * 2020-12-25 2024-01-09 天地恒一制药股份有限公司 达格列净的固体形式复合物及其制备方法与应用
WO2023144722A1 (en) * 2022-01-26 2023-08-03 Astrazeneca Ab Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
EP4493272A1 (en) * 2022-03-14 2025-01-22 University Of Virginia Patent Foundation Combination sodium-glucose cotransporter inhibitor (sglti)- insulin therapy for glycemic control in type 1 diabetes
EP4385502A1 (en) * 2022-12-15 2024-06-19 Sanovel Ilac Sanayi Ve Ticaret A.S. A pharmaceutical formulation comprising metformin, pioglitazone and a sglt-2 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
IL149851A0 (en) 2002-05-26 2002-11-10 Yeda Res & Dev Resistin binding proteins, their preparation and use
PE20090185A1 (es) * 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
WO2010045656A2 (en) * 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6013003120; Ｊ．ＭＥＤ．ＣＨＥＭ． ＶＯＬ．５１, 2008, Ｐ．１１４５-１１４９ *
JPN6013003122; ＤＩＡＢＥＴＥＳ ＶＯＬ．５７, 2008, Ｐ．１７２３-１７２９ *
JPN6014028225; ＡＢＤＵＬ-ＧＨＡＮＩ　Ｍ　Ａ: 'ＩＮＨＩＢＩＴＩＯＮ　ＯＦ　ＲＥＮＡＬ　ＧＬＵＣＯＳＥ　ＲＥＡＢＳＯＲＰＴＩＯＮ：　Ａ　ＮＯＶＥＬ　ＳＴＲＡＴＥＧＹ　ＦＯＲ　ＡＣＨＩＥＶＩＮＧ　ＧＬＵＣＯＳＥ　以下備考' ＥＮＤＯＣＲＩＮＥ　ＰＲＡＣＴＩＣＥ Ｖ１４　Ｎ６, 200809, Ｐ７８２-７９０ *
JPN6014028228; ＩＳＡＪＩ　ＭＡＳＡＹＵＫＩ: 'ＳＯＤＩＵＭ-ＧＬＵＣＯＳＥ　ＣＯＴＲＡＮＳＰＯＲＴＥＲ　ＩＮＨＩＢＩＴＯＲＳ　ＦＯＲ　ＤＩＡＢＥＴＥＳ' ＣＵＲＲＥＮＴ　ＯＰＩＮＩＯＮ　ＩＮ　ＩＮＶＥＳＴＩＧＡＴＩＯＮＡＬ　ＤＲＵＧＳ Ｖ８　Ｎ４, 20070401, Ｐ２８５-２９２, ＰＨＡＲＭＡＰＲＥＳＳ *
JPN6015013221; 膜（ＭＥＭＢＲＡＮＥ） ３３（３），　（２００８）, ｐｐ．１０２-１０７ *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523681A (ja) * 2010-03-30 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用
JP2019504090A (ja) * 2016-02-03 2019-02-14 ドクター レディズ ラボラトリーズ リミテッド ダサチニブの固体状態形態およびそれらの調製プロセス
JP2019503983A (ja) * 2016-05-20 2019-02-14 センター ラボラトリーズ， インク．Ｃｅｎｔｅｒ Ｌａｂｏｒａｔｏｒｉｅｓ， Ｉｎｃ． 高血糖症を処置する方法
JP2020100651A (ja) * 2016-05-20 2020-07-02 センター ラボラトリーズ， インク．Ｃｅｎｔｅｒ Ｌａｂｏｒａｔｏｒｉｅｓ， Ｉｎｃ． 高血糖症を処置する方法
JP2022050572A (ja) * 2016-05-20 2022-03-30 センター ラボラトリーズ， インク． 高血糖症を処置する方法
JP7266327B2 (ja) 2016-05-20 2023-04-28 センター ラボラトリーズ， インク． 高血糖症を処置する方法

Also Published As

Publication number Publication date
JP2016104753A (ja) 2016-06-09
CN106075451A (zh) 2016-11-09
WO2010138535A1 (en) 2010-12-02
US8685934B2 (en) 2014-04-01
US20120071403A1 (en) 2012-03-22
CN102639125A (zh) 2012-08-15
JP2017160212A (ja) 2017-09-14
EP2435033A1 (en) 2012-04-04

Similar Documents

Publication Publication Date Title
JP2017160212A (ja) 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法
KR101772776B1 (ko) 다파글리플로진 프로필렌 글리콜 수화물을 함유하는 제약 제형
TWI631963B (zh) 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
TW201130486A (en) Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
US12472194B2 (en) Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same
HK40048178A (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
HK1176004B (en) Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
HK1177141A (en) Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130509

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20140520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150407

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150811

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170321

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170921

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20171227